Novo Nordisk updates denecimig BLA review in US
- FDA has informed Novo the denecimig BLA review is ongoing and has not provided a new action timeline.
- The review extension is due to ongoing manufacturing facility remediation following a pre‑license inspection; no clinical efficacy or safety deficiencies were identified.
- Novo submitted the BLA in September 2025 and had anticipated an FDA decision in Q3 2026.
- Novo says the extended review does not affect its 2026 financial outlook and aims to launch denecimig in the US in the first half of 2027.
Regulatory status
Novo Nordisk says the US FDA informed the company the biologics licence application (BLA) for denecimig is still under review and that the Agency has not set a new timeline for regulatory action. Novo submitted the BLA in September 2025 and had anticipated a decision in Q3 2026.
Reason for extension
The FDA attributed the extended review time to ongoing remediation activities at the inspected manufacturing site following a pre‑license inspection. The Agency has not identified deficiencies related to the clinical efficacy or safety data submitted.
Clinical programme
The FRONTIER programme (FRONTIER1–5) underpins the development; FRONTIER2, FRONTIER3 and FRONTIER4 formed the basis of the MAA submission and evaluated monthly, two‑weekly and weekly dosing across adult and paediatric populations, including patients with inhibitors.
Product profile and timing
Denecimig is a subcutaneously administered FVIIIa‑mimetic bispecific antibody designed for monthly, Q2W and weekly prophylaxis. Novo says the FDA review delay does not affect its 2026 financial outlook and the company aims for a US launch in the first half of 2027.
Source: Novo Nordisk